KALRAY
5.7.2022 18:02:03 CEST | Business Wire | Press release
Clever Cloud , a European provider of automation and optimization solutions for websites and applications hosting, and Kalray (Paris:ALKAL) (Euronext Growth Paris: ALKAL), a leading provider of a new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, announce a partnership aimed at strengthening the relationship between the two companies for the deployment of next-generation storage solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005197/en/
Clever Cloud, which is currently setting up in a third Parisian data center and strengthening its technical platform, has chosen to partner with French company Kalray and its Flashbox™, a new generation of NVMe storage array that can accommodate up to 24 PCI Express (NVMe) SSDs, for its high-performance storage solution.
PERFORMANCE, RESILIENCE AND OPENNESS
Without a host CPU (Central Processing Unit), the Flashbox™ leverages K200-LP™ accelerator cards featuring the Coolidge™ DPU (Data Processing Unit) that takes advantage of the unique and patented MPPA® (Massively Parallel Processor Array) architecture developed by Kalray. This chip takes advantage of the power of 80 parallel cores and enables data centers adopting NVMe SSD storage to remove bottlenecks and improve performance, while consuming minimal power and resources.
A unique concept on the market today, the Flashbox™ as proposed by Kalray benefits from ultra-fast interfaces and low power consumption. It can deliver up to 12 million IOPS through a 2x 100 Gb/s network interface and is based on market standards such as Storage Performance Development Kit (SPDK), NVMe/TCP or RDMA over Converged Ethernet (RoCEv1/v2). It will eventually be offered by storage vendors using Kalray cards.
"Kalray's solution meets all our needs and the criteria that are important to us, whether in terms of sovereignty, openness, resilience, energy efficiency or performance ," said Quentin Adam, CEO of Clever Cloud.
The Flashbox™ is currently being tested in Clever Cloud's infrastructure and will join its new Paris data center where it will work alongside the latest generation of compute servers Clever Cloud is installing there. It will enable Clever Cloud to offer greater flexibility to its customers in managing storage, but also to support the launch of new offerings.
This is part of the development of Clever Cloud's Storage API, which allows various storage sources, whether local, remote or via third-party cloud service providers, to be simply allocated to the virtual machines that host users' applications. This open, multi-cloud approach is what makes Clever Cloud so successful.
CLEVER CLOUD AND KALRAY: FOR A “MADE IN FRANCE” R&D
Clever Cloud and Kalray are also partnering in several projects where they are working closely together to leverage Kalray's K200-LP™ cards as accelerators to offload Clever Cloud's network layer functionalities or computations related to the protection and redundancy of data stored within Clever Cloud's servers.
"The collaboration with Kalray is not just about two French companies that have an interest in working together, but about two projects that have, at their heart, the creation of value through innovation, where the partnership is also between the technical teams," adds Steven Le Roux, CTO of Clever Cloud .
“We are very pleased to be working with Clever Cloud, with whom we share common values, both in terms of innovation and the philosophy of our solutions, which are designed to be easy to use, flexible, scalable and open.
Kalray has a unique position in Europe in this market of very high-performance and low-power processors. We are proud to be able to build innovative French storage solutions with Clever Cloud and thus contribute to the technological sovereignty of France and Europe” , declares Eric Baissus, President and CEO of Kalray .
The Flashbox™ will be showcased at the upcoming Flash Memory Summit, a major event in the field, from August 2 to 4, 2022, in Santa Clara Convention Center, CA, USA (booth #940).
ABOUT CLEVER CLOUD
Founded in 2010, Clever Cloud is a company based in Nantes, France, and specialized in IT automation. It creates and provides the software building blocks necessary for the flexible deployment of applications on self-service PaaS architectures. Its clients include such major names as Airbus, AXA, Caisse d'Épargne, Cegid, Docaposte, MAIF, McDonald's, Solocal, SNCF, TBWA...
Website: https://www.clever-cloud.com
Latest news: https://www.clever-cloud.com/blog
ABOUT KALRAY
Kalray (Euronext Growth Paris - FR0010722819 - ALKAL) is a fabless semiconductor company, a leading provider of a new class of processors, specialized in Intelligent Data Processing from Cloud to Edge. Kalray’s team have created and developed its leading-edge technology and products to help its clients maximize the market possibilities presented by a world dominated by massive, disparate and pervasive data.
Thanks to Kalray’s patented manycore architecture, Kalray’s MPPA® Intelligent Data Processors are natively capable of managing multiple workloads with no bottlenecks to enable smarter, more efficient and energy-wise data-intensive applications. Kalray's offering includes processors, acceleration cards with associated software environment and appliances, allowing its customers to design the best solutions in fast growing sectors such as modern data centers, 5G, AI and Edge Computing, autonomous vehicles and others.
Founded in 2008 as a spin-off of CEA French lab, with investors such as Alliance Venture (Renault-Nissan-Mitsubishi), Safran, NXP Semiconductors, CEA and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: More for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005197/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom